Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is -4.87% lower on its value in year-to-date trading and has touched a low of $37.02 and a high of $60.37 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RARE stock was last observed hovering at around $40.87 in the last trading session, with the day’s loss setting it -0.85%.
Currently trading at $40.02, the stock is -6.53% and -6.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.13 million and changing -2.08% at the moment leaves the stock -15.29% off its SMA200. RARE registered -24.93% loss for a year compared to 6-month loss of -28.16%.
The stock witnessed a -9.42% gain in the last 1 month and extending the period to 3 months gives it a -15.92%, and is -4.65% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.04% over the week and 4.21% over the month.
Ultragenyx Pharmaceutical Inc (RARE) has around 1294 employees, a market worth around $3.70B and $560.23M in sales. Profit margin for the company is -101.60%. Distance from 52-week low is 8.10% and -33.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.50%).
with sales reaching $145.98M over the same period.The EPS is expected to grow by 16.82% this year, but quarterly earnings will post 16.71% year-over-year. Quarterly sales are estimated to grow 34.13% in year-over-year returns.
The shares outstanding are 92.41M, and float is at 86.48M with Short Float at 4.95%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 9.78 million shares valued at $401.98 million. The investor’s holdings represent 11.6039 of the RARE Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.6 million shares valued at $230.3 million to account for 6.648 of the shares outstanding. The other top investors are SANDS CAPITAL MANAGEMENT, LLC which holds 5.35 million shares representing 6.1847 and valued at over $220.08 million, while WELLINGTON MANAGEMENT GROUP LLP holds 5.4056 of the shares totaling 4.56 million with a market value of $187.26 million.
Ultragenyx Pharmaceutical Inc (RARE) Insider Activity
The most recent transaction is an insider sale by Kassberg Thomas Richard, the company’s CBO & EVP. SEC filings show that Kassberg Thomas Richard sold 6,028 shares of the company’s common stock on Mar 03 ’25 at a price of $42.10 per share for a total of $0.25 million. Following the sale, the insider now owns 0.27 million shares.
Ultragenyx Pharmaceutical Inc disclosed in a document filed with the SEC on Mar 03 ’25 that Parschauer Karah Herdman (EVP and Chief Legal Officer) sold a total of 12,846 shares of the company’s common stock. The trade occurred on Mar 03 ’25 and was made at $42.10 per share for $0.54 million. Following the transaction, the insider now directly holds 75287.0 shares of the RARE stock.
Still, SEC filings show that on Mar 03 ’25, Crombez Eric (EVP and Chief Medical Officer) disposed off 8,945 shares at an average price of $42.10 for $0.38 million. The insider now directly holds 71,922 shares of Ultragenyx Pharmaceutical Inc (RARE).
